The tumor-homing property of mesenchymal stem cells (MSCs) 
INTRODUCTION
Effective control of metastatic disease represents a central challenge in the treatment of solid tumors. Colorectal cancer is the third most common cancer world-wide with the liver being the most common metastatic site. While the prognosis of resectable colorectal liver metastases was improved in the recent years, 5-year survival rates after resection are still not higher than 25% to 40%, and survival rates have remained poor for unresectable disease (1) .
An emerging tumor therapy approach is based on the use of adoptively transferred mesenchymal stem cells (MSCs) as vehicles engineered to express specific reporter and/or therapy genes (eMSC). This approach utilizes the innate ability of MSCs to migrate to damaged tissue in the course of tissue repair (2). Tumors are seen by the body as chronic, never healing wounds that drive continuous tissue remodeling thus providing the basis for the marked tumor tropism of MSCs (3). We and others have harnessed this biology by using eMSC to deliver anti-cancer gene products into tumor stromal environments (4-10). Adoptively transferred MSCs are actively recruited to growing tumors where they contribute to the formation of the "benign" stromal compartment containing a variety of cell types, including endothelial cells, smooth muscle cells, and pericytes/carcinoma-associated fibroblasts (CAFs) that provide important support for the growth of solid tumors. However, MSCs also contribute to normal tissue homeostasis and therefore may also emigrate to non-tumor environments under these conditions. In order to reduce potential side effects of transgene expression in non-tumor-associated tissues, the therapeutic utility of eMSCs has been enhanced by the use of tumor stroma-specific gene promoters linked to unique differentiation pathways activated as MSC respond to tumor microenvironments. For example, the Tie2 by on . For personal use only. jnm.snmjournals.org Downloaded from promoter/enhancer is activated as MSC respond to angiogenic signals within tumor environments (7). MSC engineered to express the suicide gene herpes simplex virus thymidine kinase (HSV-TK) under control of the Tie2 promoter/enhancer showed selective expression of transgenes following systemic injection of the eMSC into mice with growing breast, pancreatic or liver tumors (7, 9) . While this approach was effective in targeting large primary tumors, the Tie2-based strategy showed low efficacy in the treatment of tumor metastases. An alternative targeting approach was therefore developed using the RANTES/CCL5 promoter to drive transgene expression in MSCs.
In the course of differentiation into CAFs, MSCs induce expression of the chemokine RANTES (11, 12) . eMSC engineered to express HSV-TK under control of the RANTES promoter in concert with GCV treatment led not only to a significant reduction in the growth of primary pancreatic carcinoma, but also dramatically reduced incidence of metastases in a pancreatic cancer model (6). Importantly, it was not possible to distinguish if this therapy effect was due to an overall reduction in metastases, or direct targeting of individual metastases.
More recently, to enhance the therapeutic potential of MSC-mediated gene therapy, a more advanced therapy gene was applied that makes use of the selective delivery of radionuclides for imaging and therapy. The sodium iodide symporter (NIS) protein is responsible for the active uptake of iodide from the blood into the thyroid gland, and as such, forms the molecular basis for the diagnostic and therapeutic use of radioiodine in the management of differentiated thyroid cancer (13) . One of the major advantages of NIS as a therapy gene is its dual function as therapy and reporter gene (13) (14) (15) (16) . MSCs engineered to express NIS can be monitored by whole body imaging using 
MATERIALS AND METHODS

Cell Culture
The establishment and characterization of MSCs has been described previously (4, 6, 18) . These cells have been previously shown to maintain their capacity to differentiate, and show migration that parallels that seen with primary cells (4, 6, 18) . The ease of expansion of clonal populations allows well controlled experimental studies.
Plasmids and their synthesis as well as the establishment of stably transfected cell lines have been described previously (4, 5).
The human colon carcinoma cell line LS174t (ATCC CCL188) was cultured in RPMI (Invitrogen/Life technologies, Darmstadt, Germany) supplemented with 10% fetal bovine serum (v/v; PAA) and 1% penicillin/streptomycin. The cell lines were maintained at 37°C and 5% CO 2 in an incubator with 95% humidity.
Establishment of a Hepatic Colon Cancer Metastases Mouse Model
The experimental protocol was approved by the regional governmental commission for 7 animals (Regierung von Oberbayern). Fully anesthetized female CD-1 nu/nu mice (Charles River, Sulzfeld, Germany) were placed in the right lateral position, after skin desinfection a 0.5 cm cut was made at the left subcostal region. 50 µl of tumor cell suspension (1x10 6 cells in 1xPBS) were then injected at the upper splenic pole using a 27-gauge needle. Abdominal wall and skin were then sutured separately using Monosyn® 5/0 fiber. 48 h later the abdominal wall was re-opened at the same site and a splenectomy was performed, followed by suturing of abdominal wall and skin. Mice were pre-and post-treated with Carprofen (5 mg/kg) to minimize wound pain. The induction of liver metastases with this technique was highly reproducible; histological liver studies showed that 90% of injected mice developed disseminated liver metastases. Animals were maintained under specific pathogen-free conditions with access to mouse chow and water ad libitum.
MSC Application and Radionuclide Biodistribution Studies in vivo
Application of eMSC was initiated five days after intrasplenic tumor cell injection, before metastatic disease was macroscopically visible. In addition, mice were pretreated with thyroid hormone L-T4 (levothyroxine) as described previously in three day intervals (n=7). As an additional control, in a subset of mice injected with RANTES-NIS-MSC (n=7) the specific NIS-inhibitor sodium-perchlorate (NaClO 4 , 2 mg/mouse) was injected intraperitoneally (i.p.) 30 min prior to radionuclide administration. 48 h after the last MSC application, 18.5 MBq radionuclide biodistribution was assessed using a gamma camera equipped with UXHR collimator (Ecam, Siemens, Germany) as described previously (19, 20) . Small-animal PET imaging was performed in a subgroup of mice treated with RANTES-NIS-MSC (n=8) receiving a dose of 12 MBq 124 I 48 h after the last MSC application, as described previously (4).
Ex Vivo Analyses of Tumor and Non-Target Tissues
For ex vivo biodistribution studies, mice were injected with RANTES-NIS-MSCs (n=15) or WT-MSCs (n=5) as described above, followed by i.p. injection of 18.5 MBq At the end of the imaging procedure, immunohistochemical and immunofluorescence staining procedures for the expression of NIS and SV40 large T Ag as well as quantification of cellular proliferation (Ki67) and blood vessel density (CD31) were performed as described previously (5).
Analysis of NIS mRNA expression using quantitative real-time PCR were performed at the end of the imaging procedure as outlined above. Total RNA was isolated from the liver and other tissues using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations and quantitative real-time PCR (qPCR) was performed as described previously (21) .
Radioiodine ( 131 I) Therapy Studies in vivo 9
Following a 10-day L-T4 pretreatment as described previously (4, 5), two groups of mice were established that each received 55. 
Magnetic Resonance Imaging (MRI)
For MRI examinations, animals were anaesthesized by i.p. injections of ketamine (Inresa Arzneimittel, Freiburg, Germany) 100mg/kg body weight) and xylazine (Bayer, Leverkusen, Germany) 10mg/kg body weight) and a 27-gauge tail vein catheter was placed for subsequent contrast media administration. MRI was performed on a clinical 3
Tesla system (Magnetom Skyra, Siemens Healthcare, Erlangen, Germany) with animals in prone position, using a clinical wrist coil (Siemens Healthcare, Erlangen, Germany).
MRI acquisition was performed using a brief imaging protocol with T1 sequences in axial and coronal view for optimal delineation of intrahepatic tumor manifestations. T1-weighted FLASH3D sequences were acquired pre-contrast and after a standardized i.v.
manual bolus injection of 100 µl of Gadolinium-based contrast medium (Primovist®, Bayer Healthcare AG, Berlin, Germany 
Statistical Methods
Statistical significance of in vitro experiments was tested using Student´s t test.
Statistical significance of the in vivo experiments has been calculated using the ManWhitney U test.
RESULTS
Radioiodine in vivo imaging studies
To evaluate the ability of eMSC to target early stages of colon cancer liver metastases, eMSC injections via the tail vein were started five days after intrasplenic injection of the human colon cancer cells LS174t before visible metastases developed, biodistribution of RANTES-NIS-MSC was then determined by 123 I-scintigraphy. Enhanced iodide uptake activity was detected in the liver area two hours after injection of 18.5 MBq 123 I (Fig. 1A) , which resulted in a maximum uptake of 12.1 ± 2.6 % ID/g with a biological half-life of 2.9 h, and a tumor absorbed dose of 63.2 mGy/mBq (Suppl. Fig. 1 ). In contrast, after injection of WT-MSC no liver-specific iodide accumulation was detected (Fig. 1C ). To further demonstrate NIS-specificity of iodide uptake in the liver region, a subset of RANTES-NIS-MSC-treated mice received NaClO 4 30 min prior to radioiodine injection, which resulted in a complete blockade of iodide accumulation in liver metastases, in addition to thyroid gland and stomach (Fig. 1B) , which represent physiologically NIS- I application (Fig. 1D, E) . In 70% of RANTES-NIS-MSC-treated mice a maximum uptake of 16.2 ± 3.5 % ID/g was measured in single nodules.
Ex vivo radioiodine biodistribution study
Ex vivo gamma counter analysis of radioiodine biodistribution was performed which confirmed increased iodide uptake (approximately 6.1 ± 1.1 % ID/g) in the liver of RANTES-NIS-MSC-treated mice 3 hours after 123 I injection (Fig. 2) . In contrast, mice injected with WT-MSCs showed no significant hepatic iodide uptake and no significant iodide uptake levels were observed in non-target organs (Fig. 2) . In both groups, the thyroid gland and the stomach accumulated approx. 40% and 39%
123
I ID/organ, respectively, resulting from endogenous expression of NIS in these organs (data not shown). In additional control mice injected with RANTES-NIS-MSC, administration of the competitive inhibitor perchlorate resulted in a blockade of iodide uptake in liver (Fig. 2) as well as thyroid gland and stomach (data not shown).
Immunohistochemical analysis of eMSC / transgene biodistribution SV40 large T Ag was used to immortalize the MSCs and could thus be used as target to assess the biodistribution of eMSCs, while human NIS-specific antibodies allowed the determination of RANTES promoter-induced NIS transgene expression. Paraffinembedded tissues from liver and additional "non-target" organs (lung, kidneys) were processed for immunohistochemical staining using both sets of antibodies. In liver metastases of mice treated with RANTES-NIS-MSCs, NIS-specific immunoreactivity was confined to metastatic nodules, and no NIS-specific staining was seen in the surrounding normal liver tissue (Fig. 3A) . This biodistribution pattern was confirmed by SV40 large T Ag-specific staining (Fig. 3C) . Systemic injection of WT-MSCs showed no NIS-specific immunoreactivity in metastases or in normal liver tissue (Fig. 3B) ; However, SV40 large T Ag staining still demonstrated active WT-MSC recruitment into the metastatic nodules (Fig. 3D) , thus supporting tumor-selective eMSC recruitment.
Immunofluorescence analysis confirmed co-localization of NIS-and SV40 large T Ag staining in the stroma of liver metastases of tumor-bearing mice after injection of Fig. 2A -C) .
RANTES-NIS-MSC (Suppl
In non-target organs such as lung or kidney, no NIS-specific or SV40 large T Ag-specific staining was detected in mice treated with RANTES-NIS-MSCs (Suppl. Fig. 2D -G) .
Analysis of NIS mRNA expression
Metastatic livers from mice treated with RANTES-NIS-MSCs revealed a 7.6-fold increased level of NIS mRNA expression as compared to metastatic livers from mice treated with WT-MSCs. As expected, additional treatment with the competitive NIS inhibitor perchlorate (NaClO 4 ) had no influence on NIS mRNA expression in metastasesbearing mice injected with RANTES-NIS-MSC (7.4-fold increase). In contrast, non-target organs like lung or kidney showed no NIS mRNA expression in RANTES-NIS-MSC-or WT-MSC-treated mice (Suppl. Fig. 3 ).
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I therapy study
The therapeutic effect of 131 I was assessed using the therapy regimen optimized in previous studies (4, 5). The protocol is based on three cycles of eMSC injections followed by 131 I (Fig. 4A) . After systemic injection of RANTES-NIS-MSC followed by 131 I injection a significantly improved survival of up to 14 days was observed as compared to control groups (Fig. 4A) . 4C ) as compared to a tumor load of at least 90% in the control group (RANTES-NIS-MSC + NaCl) (Fig. 4D) . Mice in the control groups did not survive long enough to receive the final 131 I or saline application.
At the end of experiments, animals were sacrificed, and their organs removed and characterized by immunofluorescence analysis for cellular proliferation (Ki67, green) and blood vessel density (CD31, red) markers. The results showed striking differences between therapy and control groups (Suppl. Fig. 4A -C) . Mice treated with RANTES-NIS-MSCs followed by 131 I showed decreased proliferation (Ki67: 23.3% ± 2.5%) and blood vessel density (CD31: 3.1% ± 0.2%), whereas control mice treated with RANTES-NIS-MSC followed by NaCl or treated with WT-MSCs followed by CD31: 7.8% ± 0.8%) and high levels of proliferation (RANTES-NIS-MSC + NaCl: Ki67:
73.8% ± 6.9%; WT-MSC + 131 I: Ki67: 76.5% ± 6,7%) (Suppl. Fig. 4D, E) .
DISCUSSION
In the present study, an emerging gene therapy approach was evaluated where the therapy gene was expressed in the context of eMSC-based protocols -specifically for treatment of metastatic disease. eMSCs are excellent gene delivery vehicles based in part on their relative ease of engineering and expansion in vitro. Importantly, these cells also show a remarkable natural tropism for solid tumors (22, 23) . An array of therapy proteins have already been demonstrated to be successfully delivered to tumor environments using eMSC, including interferon-gamma, TRAIL ligands, IL-12, the chemokine CX3CL1, as well as various suicide genes (4, 5, 24, 25) . Recent studies have shown that adoptively applied MSC can also efficiently home to tumor metastases opening the door to the potential use of eMSC for treatment of metastatic disease (26-
29).
In a recent study, using experimental models of melanoma, breast and hepatoma tumors the authors used an IL-12-based eMSC approach that showed reduced progression of metastases at midstage of development, and even regression at later stages following an extended course of i.v. immunotherapy using IL-12 gene-engineered MSCs (29) . In a model of metastatic breast cancer, Zhao et al. showed that, human neural stem cells (NSC) engineered to constitutively secrete the suicide gene carboxylesterase, were also able to target tumor metastases in multiple organs including liver, lymph nodes, and lung (27) .
The downside of gene therapy using traditional suicide genes is that even though they act through bystander killing, their effects are limited to the cells most proximal to the transgene expressing cells. In contrast, NIS-targeted radioiodine therapy is associated with a higher degree of bystander killing effect that results from the crossfire effect of the β-emitter 131 I and from the radiation-induced biological bystander effect. This therapy concept has been effectively used for the treatment of differentiated thyroid cancer for almost 70 years and still represents one of the most effective systemic anticancer radiotherapies available to the clinician today.
The application of the NIS gene as a combined imaging/therapy gene has been an area of expanded research in various tumor settings over the past few years (13) (14) (15) (16) (17) . The ability to non-invasively monitor the biodistribution of NIS expression after systemic gene I-based radiotherapy after systemic application (37, 38) .
In previous studies we demonstrated a proof of concept of systemic NIS gene delivery using MSCs as delivery vehicles using subcutaneous xenograft mouse models (4, 5). In therapy studies a significant reduction of tumor load in the liver was observed from at least 90% in the control groups to approx. 60% in the therapy group starting with 40% tumor load prior to the first extended life span -which is highly significant considering the aggressive growth of tumor metastases in this model. These findings correlate with markedly reduced proliferation and blood vessel density in the tumors of the therapy group.
In contrast to our study, previous studies of gene therapy of metastatic disease analyzed therapeutic efficacy ex vivo. Zischek et al. showed reduced level of metastases in a pancreatic carcinoma mouse model by ex vivo analysis of tumor growth after treatment with MSCs expressing the HSV-TK suicide gene (6). With the translation from animal to human studies in mind, in the present study we used contrast enhanced MRI to monitor the growth of hepatic colon cancer metastases over time in vivo. MRI is emerging as a powerful method to investigate the potential effects of treatment approaches in mice.
The contrast between tumor and normal tissue was enhanced by a liver-specific contrast agent (Primovist®), which allowed an optimal evaluation of treatment effects in hepatic metastases (39) .
We are aware that with the mouse model used in this study based on metastases of human colon cancer cells to the liver in athymic nude mice, the influence of the immune system on MSC biodistribution as well as on tumor growth and therapeutic efficacy of MSC-mediated NIS radionuclide therapy cannot be investigated and will be addressed in future studies. MSCs are known to have immunosuppressive functions that may influence therapeutic efficacy. However, previous studies from our group using 
